About: Development of broad‐spectrum human monoclonal antibodies for rabies post‐exposure prophylaxis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development of broad‐spectrum human monoclonal antibodies for rabies post‐exposure prophylaxis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Development of broad‐spectrum human monoclonal antibodies for rabies post‐exposure prophylaxis
Creator	Corti, Davide Lanzavecchia, Antonio Sallusto, Federica Wright, Edward Cattoli, Giovanni Capua, Ilaria De Benedictis, Paola Bourhy, Hervé Minola, Andrea Foglierini, Mathilde Vanzetta, Fabrizia Agatic, Gloria Aiello, Roberta Bentley, Emma Lavenir, Rachel Lepelletier, Anthony Salomoni, Angela Weiss, Robin Zecchin, Barbara Nodari, Elena
Source	Medline; PMC
abstract	Currently available rabies post‐exposure prophylaxis (PEP) for use in humans includes equine or human rabies immunoglobulins (RIG). The replacement of RIG with an equally or more potent and safer product is strongly encouraged due to the high costs and limited availability of existing RIG. In this study, we identified two broadly neutralizing human monoclonal antibodies that represent a valid and affordable alternative to RIG in rabies PEP. Memory B cells from four selected vaccinated donors were immortalized and monoclonal antibodies were tested for neutralizing activity and epitope specificity. Two antibodies, identified as RVC20 and RVC58 (binding to antigenic site I and III, respectively), were selected for their potency and broad‐spectrum reactivity. In vitro, RVC20 and RVC58 were able to neutralize all 35 rabies virus (RABV) and 25 non‐RABV lyssaviruses. They showed higher potency and breath compared to antibodies under clinical development (namely CR57, CR4098, and RAB1) and commercially available human RIG. In vivo, the RVC20–RVC58 cocktail protected Syrian hamsters from a lethal RABV challenge and did not affect the endogenous hamster post‐vaccination antibody response.
has issue date	2016-03-18(xsd:dateTime)
bibo:doi	10.15252/emmm.201505986
bibo:pmid	26992832
has license	cc-by
sha1sum (hex)	3656fed9d1f687fd87440d7da4f3d852aa1dcdc4
schema:url	https://doi.org/10.15252/emmm.201505986
resource representing a document's title	Development of broad‐spectrum human monoclonal antibodies for rabies post‐exposure prophylaxis
has PubMed Central identifier	PMC4818751
has PubMed identifier	26992832
schema:publication	EMBO Mol Med
resource representing a document's body	covid:3656fed9d1f687fd87440d7da4f3d852aa1dcdc4#body_text
is schema:about of	named entity 'HUMAN' named entity 'PEP' named entity 'vaccinated' named entity 'immortalized' named entity 'rabies' named entity 'CLINICAL DEVELOPMENT' named entity 'HIGH' named entity 'CHALLENGE' named entity 'STUDY' named entity 'USE' named entity 'NON-' named entity 'ENDOGENOUS' named entity 'REPRESENT' named entity 'COCKTAIL' named entity 'EQUINE' named entity 'COSTS' named entity 'LETHAL' named entity 'HUMANS' named entity 'RABV' named entity 'POST-EXPOSURE PROPHYLAXIS' named entity 'RABIES' named entity 'BROAD' named entity 'REPLACEMENT' named entity 'IMMORTALIZED' named entity 'IDENTIFIED' named entity 'AFFECT' named entity 'INCLUDES' named entity 'DUE TO' named entity 'DID' named entity 'BROAD' named entity 'SPECTRUM' named entity 'MONOCLONAL ANTIBODIES' named entity 'HAMSTER' named entity 'COMPARED' named entity 'REACTIVITY' named entity 'PRODUCT' named entity 'POST-EXPOSURE PROPHYLAXIS' named entity 'ALTERNATIVE' named entity 'SPECIFICITY' named entity 'AVAILABILITY OF' named entity 'ANTIBODIES' named entity 'EPITOPE' named entity 'DONORS' named entity 'SITE' named entity 'AVAILABLE' named entity 'SELECTED' named entity 'IN VIVO' named entity 'RABIES' named entity 'SPECTRUM' named entity 'III' named entity 'HUMAN' named entity 'HUMAN RABIES' named entity 'RIG' named entity 'IN VITRO' named entity 'PEP' named entity 'POTENCY' named entity 'RABIES VIRUS' named entity 'VALID' named entity 'MEMORY B CELLS' named entity 'IMMUNOGLOBULINS' named entity 'TESTED FOR' named entity 'LIMITED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software